会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Peptide, a bronchus-expanding agent, and a blood-flow-improving agent
    • 肽,支气管扩张剂和血液流动改善剂
    • US5856303A
    • 1999-01-05
    • US776815
    • 1997-02-07
    • Kazuhisa KashimotoYumiko Nagano
    • Kazuhisa KashimotoYumiko Nagano
    • A61K38/00A61P7/00C07K14/575C07K14/605C07K5/00C07K7/00
    • C07K14/605C07K14/575C07K14/57563A61K38/00
    • The present invention relates to a peptide represented by the general formula (1): ##STR1## wherein A is Ala or Gly; B is Ile or Val; C is Asn or Ser; D is Thr or Ser; E is Leu or Tyr; each of F, I and J is Lys or Arg, and at least one of F, I and J is Arg; G is Met, Leu or Nle; K is Asn or Ala; L is Ser or Ala; M is Ile or Val; and N is --NH.sub.2 or Asn--NH.sub.2, excluding the combination where A is Ala, B is Val, C is Asn, D is Thr, E is Leu, K is Asn, L is Ser, M is Ile, and N is Asn--NH.sub.2, and pharmaceutically acceptable salts thereof, as well as to a bronchus-expanding agent or a blood-flow-improving agent comprising said peptide or a pharmaceutically acceptable salt thereof as an active ingredient.
    • PCT No.PCT / JP96 / 01543 Sec。 371日期1997年2月7日 102(e)1997年2月7日PCT PCT 1996年6月6日PCT公布。 出版物WO96 / 41814 PCT 日期:1996年12月27日本发明涉及由通式(1)表示的肽:HHisSerAspABPheThrAspCTyrD(1)ArgEArgFGlnGAlaValIJTyrLeuKLMLeuN其中A为Ala或Gly; B是Ile或Val; C是Asn或Ser; D是Thr或Ser; E是Leu或Tyr; F,I和J各自为Lys或Arg,F,I和J中的至少一个为Arg; G为Met,Leu或Nle; K为Asn或Ala; L是Ser或Ala; M是Ile或Val; N为-NH 2或Asn-NH 2,不包括A为Ala的组合,B为Val,C为Asn,D为Thr,E为Leu,K为Asn,L为Ser,M为Ile,N为Asn -NH 2及其药学上可接受的盐,以及包含所述肽或其药学上可接受的盐作为活性成分的支气管扩张剂或血液流动改进剂。
    • 5. 发明授权
    • Process for producing LH-RH derivatives
    • 生产LH-RH衍生物的方法
    • US06448031B1
    • 2002-09-10
    • US09463947
    • 2000-02-04
    • Kazuhisa KashimotoYumiko NaganoAkiko Ohata
    • Kazuhisa KashimotoYumiko NaganoAkiko Ohata
    • C12P2106
    • C07K5/0825C07K7/23
    • This invention relates to a method for producing an LH-RH derivative, characterized in that a peptide fragment shown by general formula (1): pGlu-His-Trp-OR1 (where R1 denotes a lower alkyl) and a peptide fragment shown by general formula (2): H-Ser-Tyr-X-Leu-Arg-Pro-Y (where X denotes an amino acid selected from the group consisting of D-amino acids such as D-Leu, D-Ser(But), D-Trp, and (2-napthyl)-D-Ala, and Gly, and Y denotes Gly-NH2, Azgly(Azaglycine)-NH2 or NHR2 (R2 is lower alkyl)) are allowed to react in the presence of chymotrypsin or a chymotrypsin-like enzymes, to produce the LH-RH derivative shown by general formula (3): pGlu-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y (where X and Y are as defined above). Since the method does not accompany a side reaction such as racemization, it enables simple separation and purification of LH-RH derivatives. Moreover the method enables to provide high yields, as well as recovery and recycling of unreacted peptide fragments, therefore it is valuable in industrial use.
    • 本发明涉及一种LH-RH衍生物的制造方法,其特征在于,通式(1)表示的肽片段:pGlu-His-Trp-OR1(其中R1表示低级烷基)和通式 式(2):H-Ser-Tyr-X-Leu-Arg-Pro-Y(其中X表示选自D-氨基酸如D-Leu,D-Ser(But), D-Trp和(2-萘基)-D-Ala,Gly和Y表示Gly-NH2,Azgly(Azaglycine)-NH2或NHR2(R2是低级烷基))在糜蛋白酶或 (3)所示的LH-RH衍生物:pGlu-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y(其中X和Y如上定义) 。 由于该方法不伴随诸如外消旋化的副反应,因此能够简单地分离和纯化LH-RH衍生物。 此外,该方法能够提供高产率,以及未反应的肽片段的回收和再循环,因此它在工业上是有价值的。